Pancreatic Cancer Research

ResearcherKyushu UniversityActive in the last 2 years

Kohei Nakata

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5717-8569; OpenAlex author ID A5056976194, A5102989178. Sources: OpenAlex.

Their work

Papers
62 (first author 13, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
146
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: 6 papers · 2018: 3 papers · 2019: 5 papers · 2020: 4 papers · 2021: 5 papers · 2022: 5 papers · 2023: 8 papers · 2024: 11 papers · 2025: 7 papers · 2026: 5 papers

Papers 50 of 62

  1. Neoadjuvant and adjuvant treatment for pancreatic ductal adenocarcinoma in patients over 80 years old based on a nationwide clinical database. Co-author DOI 10.1007/s00535-026-02480-8↗
  2. Long-term outcomes of plastic versus metal stents for preoperative biliary drainage in pancreatic cancer: a nationwide propensity score-matched analysis. Co-author DOI 10.1016/j.gie.2026.05.032↗
  3. S100A6 expression in resected specimens predicts lymph node metastasis in small pancreatic ductal adenocarcinoma: A retrospective cohort study. Co-author DOI 10.1016/j.surg.2026.110423↗
  4. Clinical Practice Guidelines for Pancreatic Cancer 2025 From the Japan Pancreas Society: A Synopsis. Co-author DOI 10.1097/mpa.0000000000002600↗
  5. Clinical Statistics and Outcomes of Pancreatic Neoplasms in Japan: A Retrospective Cohort Study Using the Japan Pancreatic Cancer Registry. Co-author DOI 10.1097/mpa.0000000000002694↗
  6. Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: … Co-author DOI 10.1002/jhbp.12181↗
  7. Identification of cold tumor induction-related markers in pancreatic cancer and the clinical implication of PCDH7. Co-author DOI 10.1007/s00432-025-06095-z↗
  8. Prognostic Significance of Desmoplastic Reaction Classification and Its Association With Stromal Biomarkers in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.modpat.2025.100865↗
  9. Clinical efficacy of pancreas-preserving distal pancreatectomy for the treatment of pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.surg.2024.108958↗
  10. uPAR expression in M-MDSCs under high LDHA activity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-025-29823-4↗
  11. Risk Factors for Early Recurrence of Resectable Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17792↗
  12. Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study. First author DOI 10.3389/fimmu.2025.1571182↗
  13. MicroRNA-20a in extracellular vesicles derived from duodenal fluid is a possible biomarker for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/deo2.333↗
  14. Patient-derived organoids of pancreatic ductal adenocarcinoma for subtype determination and clinical outcome prediction. Co-author DOI 10.1007/s00535-024-02103-0↗
  15. Identification of a urinary CD276 fragment for detecting resectable pancreatic cancer using a C-terminal proteomics strategy. Co-author DOI 10.1038/s41598-024-65093-2↗
  16. Immature stroma and high infiltration of CD15+ cells are predictive markers of poor prognosis in different subsets of patients with pancreatic cancer. Co-author DOI 10.1111/cas.16060↗
  17. Combined Autophagy Inhibition and Dendritic Cell Recruitment Induces Antitumor Immunity and Enhances Immune Checkpoint Blockade Sensitivity in Pancreatic Cance… First author DOI 10.1158/0008-5472.can-24-0830↗
  18. TAK1 Promotes an Immunosuppressive Tumor Microenvironment through Cancer-Associated Fibroblast Phenotypic Conversion in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-1004↗
  19. A multi-institutional randomized phase III study comparing minimally invasive distal pancreatectomy versus open distal pancreatectomy for pancreatic cancer; Ja… Co-author DOI 10.1186/s12885-024-11957-9↗
  20. Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells. First author DOI 10.1186/s13046-024-03060-5↗
  21. Tumor-associated neutrophils upregulate Nectin2 expression, creating the immunosuppressive microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03178-6↗
  22. Dynamic glycolytic reprogramming effects on dendritic cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03192-8↗
  23. [Microbiome in the Therapy for the Pancreatic Cancer]. Co-author PMID 39009514↗
  24. Involvement of angiogenesis in cancer-associated acinar-to-ductal metaplasia lesion of pancreatic cancer invasive front. Co-author DOI 10.1007/s00432-022-04554-5↗
  25. Minimally invasive distal pancreatectomy for pancreatic cancer: cranial-to-caudal approach with identification of Gerota's fascia (with video). Co-author DOI 10.1007/s00464-023-10438-7↗
  26. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  27. Clinical Implications of FDG-PET in Pancreatic Ductal Adenocarcinoma Patients Treated with Neoadjuvant Therapy. First author DOI 10.1007/s11605-023-05591-2↗
  28. Extracellular volume fraction determined by dual-layer spectral detector CT: Possible role in predicting the efficacy of preoperative neoadjuvant chemotherapy … Co-author DOI 10.1016/j.ejrad.2023.110756↗
  29. Intratumor Fusobacterium nucleatum promotes the progression of pancreatic cancer via the CXCL1-CXCR2 axis. Co-author DOI 10.1111/cas.15901↗
  30. A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arte… Co-author DOI 10.1245/s10434-022-12566-1↗
  31. Prognostic Impact of Preoperative Osteosarcopenia for Patients with Pancreatic Ductal Adenocarcinoma After Curative Resection. First author DOI 10.1245/s10434-023-13936-z↗
  32. Extensive (subtotal) distal pancreatectomy for pancreatic ductal adenocarcinoma: a propensity score matched cohort study of short- and long-term outcomes compa… First author DOI 10.1007/s00423-022-02453-4↗
  33. Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer: a single-center retrospective study. Co-author DOI 10.1007/s12672-021-00462-1↗
  34. Prediction of pathological response to preoperative chemotherapy for pancreatic ductal adenocarcinoma using 2-[18F]-fluoro-2-deoxy-d-glucose positron-emission … Co-author DOI 10.1016/j.crad.2022.03.001↗
  35. Circulating CD8+CD122+ T cells as a prognostic indicator of pancreatic cancer. Co-author DOI 10.1186/s12885-022-10207-0↗
  36. Subtypes in pancreatic ductal adenocarcinoma based on niche factor dependency show distinct drug treatment responses. Co-author DOI 10.1186/s13046-022-02301-9↗
  37. FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience. Co-author DOI 10.1007/s00595-020-02123-2↗
  38. Bone marrow-derived macrophages converted into cancer-associated fibroblast-like cells promote pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2021.04.013↗
  39. New high-throughput screening detects compounds that suppress pancreatic stellate cell activation and attenuate pancreatic cancer growth. First author DOI 10.1016/j.pan.2021.04.002↗
  40. Risk Factors for Gemcitabine-Induced Vascular Pain in Patients With Pancreatic Cancer. Co-author DOI 10.1177/1060028020969354↗
  41. Efficient pre-treatment for pancreatic cancer using chloroquine-loaded nanoparticles targeting pancreatic stellate cells. First author DOI 10.3892/ol.2021.12894↗
  42. Is remnant pancreatic cancer after pancreatic resection more frequent in early-stage pancreatic cancer than in advanced-stage cancer? Co-author DOI 10.1002/ags3.12340↗
  43. High-risk lesions in the remnant pancreas: fate of the remnant pancreas after pancreatic resection for pancreatic cancer and intraductal papillary mucinous neo… Co-author DOI 10.1007/s00595-019-01852-3↗
  44. Necroptosis in pancreatic cancer promotes cancer cell migration and invasion by release of CXCL5. Co-author DOI 10.1371/journal.pone.0228015↗
  45. Neutrophil extracellular traps promote liver micrometastasis in pancreatic ductal adenocarcinoma via the activation of cancer‑associated fibroblasts. Co-author DOI 10.3892/ijo.2019.4951↗
  46. CD110 promotes pancreatic cancer progression and its expression is correlated with poor prognosis. Co-author DOI 10.1007/s00432-019-02860-z↗
  47. Cancer-associated acinar-to-ductal metaplasia within the invasive front of pancreatic cancer contributes to local invasion. Co-author DOI 10.1016/j.canlet.2018.12.005↗
  48. Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-019-07269-z↗
  49. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery. Co-author DOI 10.1245/s10434-019-07309-8↗
  50. S100P regulates the collective invasion of pancreatic cancer cells into the lymphatic endothelial monolayer. Co-author DOI 10.3892/ijo.2019.4812↗

Closest collaborators

The 25 strongest of 146 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Naoki Ikenaga · 27 shared papers, 2011–2026 · strength 4.44
  2. Kenoki Ohuchida · 37 shared papers, 2011–2026 · strength 4.43
  3. Masafumi Nakamura · 32 shared papers, 2017–2026 · strength 4.39
  4. Yoshinao Oda · 30 shared papers, 2011–2026 · strength 3.98
  5. Toshiya Abe · 29 shared papers, 2017–2026 · strength 3.84
  6. Chika Iwamoto · 21 shared papers, 2017–2025 · strength 2.74
  7. Takao Ohtsuka · 25 shared papers, 2017–2026 · strength 2.56
  8. Noboru Ideno · 14 shared papers, 2022–2026 · strength 2.53
  9. Yoshihiro Miyasaka · 22 shared papers, 2017–2025 · strength 1.99
  10. Masafumi Nakamura · 15 shared papers, 2017–2025 · strength 1.83
  11. Koji Shindo · 12 shared papers, 2019–2025 · strength 1.59
  12. Kousei Ishigami · 8 shared papers, 2022–2025 · strength 1.39
  13. Koki Oyama · 8 shared papers, 2022–2025 · strength 1.36
  14. Nao Fujimori · 8 shared papers, 2019–2025 · strength 1.27
  15. Chikanori Tsutsumi · 6 shared papers, 2024–2025 · strength 1.13
  16. Yasuhisa Mori · 9 shared papers, 2017–2025 · strength 1.07
  17. Tomohiko Shinkawa · 7 shared papers, 2020–2025 · strength 1.04
  18. Masataka Hayashi · 6 shared papers, 2023–2024 · strength 1.03
  19. Atsushi Masamune · 4 shared papers, 2026 · strength 0.97
  20. Nobuhiro Fujita · 5 shared papers, 2023–2025 · strength 0.97
  21. Kazuhiro Koikawa · 12 shared papers, 2017–2024 · strength 0.96
  22. Hideya Onishi · 5 shared papers, 2019–2026 · strength 0.89
  23. Sohei Satoi · 4 shared papers, 2025–2026 · strength 0.87
  24. Masamichi Mizuma · 4 shared papers, 2025–2026 · strength 0.87
  25. Michiaki Unno · 4 shared papers, 2024–2026 · strength 0.86

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.